Concha N O, Janson C A, Rowling P, Pearson S, Cheever C A, Clarke B P, Lewis C, Galleni M, Frère J M, Payne D J, Bateson J H, Abdel-Meguid S S
Department of Structural Biology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA.
Biochemistry. 2000 Apr 18;39(15):4288-98. doi: 10.1021/bi992569m.
Metallo beta-lactamase enzymes confer antibiotic resistance to bacteria by catalyzing the hydrolysis of beta-lactam antibiotics. This relatively new form of resistance is spreading unchallenged as there is a current lack of potent and selective inhibitors of metallo beta-lactamases. Reported here are the crystal structures of the native IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor, 2-[5-(1-tetrazolylmethyl)thien-3-yl]-N-[2-(mercaptomethyl)-4 -(phenylb utyrylglycine)]. The structures were determined by molecular replacement, and refined to 3.1 A (native) and 2.0 A (complex) resolution. Binding of the inhibitor in the active site induces a conformational change that results in closing of the flap and transforms the active site groove into a tunnel-shaped cavity enclosing 83% of the solvent accessible surface area of the inhibitor. The inhibitor binds in the active site through interactions with residues that are conserved among metallo beta-lactamases; the inhibitor's carboxylate group interacts with Lys161, and the main chain amide nitrogen of Asn167. In the "oxyanion hole", the amide carbonyl oxygen of the inhibitor interacts through a water molecule with the side chain of Asn167, the inhibitor's thiolate bridges the two Zn(II) ions in the active site displacing the bridging water, and the phenylbutyryl side chain binds in a hydrophobic pocket (S1) at the base of the flap. The flap is displaced 2.9 A compared to the unbound structure, allowing Trp28 to interact edge-to-face with the inhibitor's thiophene ring. The similarities between this inhibitor and the beta-lactam substrates suggest a mode of substrate binding and the role of the conserved residues in the active site. It appears that the metallo beta-lactamases bind their substrates by establishing a subset of binding interactions near the catalytic center with conserved characteristic chemical groups of the beta-lactam substrates. These interactions are complemented by additional nonspecific binding between the more variable groups in the substrates and the flexible flap. This unique mode of binding of the mercaptocarboxylate inhibitor in the enzyme active site provides a binding model for metallo beta-lactamase inhibition with utility for future drug design.
金属β-内酰胺酶通过催化β-内酰胺类抗生素的水解赋予细菌抗生素抗性。由于目前缺乏有效的金属β-内酰胺酶选择性抑制剂,这种相对较新的耐药形式正在毫无阻碍地传播。本文报道了来自铜绿假单胞菌的天然IMP-1金属β-内酰胺酶及其与巯基羧酸盐抑制剂2-[5-(1-四唑基甲基)噻吩-3-基]-N-[2-(巯基甲基)-4-(苯基丁酰基)甘氨酸]复合物的晶体结构。结构通过分子置换法确定,并分别精修至3.1 Å(天然结构)和2.0 Å(复合物结构)分辨率。抑制剂在活性位点的结合诱导了构象变化,导致瓣片关闭,并将活性位点凹槽转变为一个隧道形腔,该腔包围了抑制剂83%的溶剂可及表面积。抑制剂通过与金属β-内酰胺酶中保守的残基相互作用而结合在活性位点;抑制剂的羧酸盐基团与Lys161相互作用,Asn167的主链酰胺氮也参与其中。在“氧阴离子洞”中,抑制剂的酰胺羰基氧通过一个水分子与Asn167的侧链相互作用,抑制剂的硫醇盐桥接活性位点中的两个Zn(II)离子,取代了桥连水分子,苯基丁酰基侧链结合在瓣片底部的一个疏水口袋(S1)中。与未结合结构相比,瓣片位移了2.9 Å,使得Trp28能够与抑制剂的噻吩环进行面对面相互作用。该抑制剂与β-内酰胺底物之间的相似性表明了底物结合模式以及活性位点中保守残基的作用。看来金属β-内酰胺酶通过在催化中心附近与β-内酰胺底物的保守特征化学基团建立一组结合相互作用来结合其底物。这些相互作用通过底物中更多可变基团与柔性瓣片之间的额外非特异性结合得到补充。巯基羧酸盐抑制剂在酶活性位点的这种独特结合模式为金属β-内酰胺酶抑制提供了一个结合模型,对未来药物设计具有实用价值。